Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + Olaparib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Soft Tissue Sarcoma
Conditions
Advanced Soft Tissue Sarcoma
Trial Timeline
May 20, 2020 → Nov 29, 2024
NCT ID
NCT03838744About Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + Olaparib
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + Olaparib is a phase 2 stage product being developed by AstraZeneca for Advanced Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03838744. Target conditions include Advanced Soft Tissue Sarcoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Soft Tissue Sarcoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03838744 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Soft Tissue Sarcoma